Prenatal Testing And Newborn Screening Market Overview
The Prenatal Testing And Newborn Screening Market is witnessing steady growth as awareness of prenatal care increases and healthcare providers place greater emphasis on early detection of genetic, metabolic, and other disorders. The market was valued at USD 6.6 billion in 2024 and reached USD 6.9 billion in 2025. It is projected to reach USD 12 billion by 2035, expanding at a CAGR of 5.6% during the forecast period.
North America is expected to remain the leading regional market, supported by advanced healthcare infrastructure, high healthcare expenditure, and growing demand for preventive healthcare services. The North American market was valued at USD 2.5 billion in 2024 and is projected to reach USD 4.5 billion by 2035. Non-Invasive Prenatal Testing represents the largest test-type segment, valued at USD 3 billion in 2024 and projected to reach USD 5 billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=634747
Key Companies in the Prenatal Testing And Newborn Screening Market
Illumina
Natera
BD
Abbott Laboratories
PerkinElmer
BioRad Laboratories
F. HoffmannLa Roche
Roche
Mayo Clinic
Hologic
Qiagen
Siemens Healthineers
Thermo Fisher Scientific
GE Healthcare
Agilent Technologies
The Prenatal Testing And Newborn Screening Market is being driven by the rising incidence of genetic disorders, increasing awareness of prenatal health, technological advancements in testing, favorable reimbursement policies, and growing healthcare expenditure. The adoption of non-invasive prenatal testing is increasing because of its safety and convenience, while molecular, biochemical, and immunologic testing technologies are improving detection capabilities and supporting earlier intervention.
The market is segmented by Test Type, Technology, Application, End Use, and Region. By Test Type, it includes Non-Invasive Prenatal Testing, Invasive Prenatal Testing, and Newborn Screening Tests. By Technology, the market covers Molecular Testing, Biochemical Testing, and Immunologic Testing. Applications include Genetic Disorders, Metabolic Disorders, and Hemoglobin Disorders, while end users comprise Hospitals, Diagnostic Laboratories, and Prenatal Clinics.
Significant opportunities exist through the growing demand for non-invasive testing, innovative biomarker discovery technologies, advanced genetic testing, and expanded newborn screening programs. Artificial intelligence and machine learning can enhance predictive analytics and risk assessment, while telehealth and mobile health applications can improve access to screening information and consultations, particularly in underserved areas.
Recent Developments and Market Trends:
Roche announced a strategic partnership with Mayo Clinic in March 2025 to co-develop and validate expanded non-invasive prenatal testing panels using cell-free DNA and advanced sequencing technologies.
Illumina announced the acquisition of Verinata Health’s prenatal testing assets in June 2024 to strengthen its NIPT portfolio and expand fetal genetic screening offerings.
PerkinElmer introduced a newborn screening platform upgrade in April 2025, incorporating enhanced automation and analytics for population-level screening.
Non-invasive prenatal testing is gaining adoption because it provides a safer and more convenient approach to detecting fetal genetic abnormalities.
Artificial intelligence and machine learning are emerging as tools for improving predictive analytics and risk assessment in prenatal testing.
Point-of-care testing solutions are creating opportunities for faster screening and improved accessibility.
Personalized healthcare approaches are increasing demand for testing strategies tailored to individual maternal and newborn needs.
Governments and healthcare systems are expanding newborn screening programs to support earlier diagnosis and intervention.
Asia-Pacific is expected to offer significant growth opportunities as healthcare access, disposable incomes, technological adoption, and maternal and infant health initiatives improve.
Reasons to Buy the Report:
Understand the current market size and projected growth of the global Prenatal Testing And Newborn Screening Market.
Analyze key growth drivers including genetic disorders, technological advancements, healthcare awareness, reimbursement policies, and healthcare expenditure.
Evaluate opportunities across test types, technologies, applications, end users, and regional markets.
Assess the competitive landscape and strategies of leading prenatal testing and newborn screening companies.
Understand the impact of NIPT, molecular testing, AI, machine learning, and point-of-care technologies on market development.
Identify opportunities associated with expanded newborn screening programs, telehealth, biomarker discovery, and personalized healthcare.
Future Outlook:
The Prenatal Testing And Newborn Screening Market is expected to maintain steady growth through 2035 as demand for early detection of genetic and congenital disorders continues to increase. North America is expected to remain the leading regional market, while Asia-Pacific offers significant expansion potential as healthcare infrastructure, awareness, and access to advanced testing improve. Continued innovation in non-invasive testing, molecular diagnostics, artificial intelligence, biomarker discovery, point-of-care solutions, and digital healthcare is expected to shape the market’s future. With the market projected to reach USD 12 billion by 2035 at a CAGR of 5.6%, opportunities remain strong for companies developing accurate, accessible, and advanced prenatal and newborn screening solutions.
➤➤Explore Our Latest Related Reports:
